Serial Number
98727351
Owner
SEED Therapeutics US, Inc.Attorney
Ian W. GilliesFirst Use Date
Jan 28, 2025
Filing Date
Aug 30, 2024
RITE3 Trademark
Serial Number: 98727351 • Registration: 8245651
Trademark Classes
Owner Contact Info
411 Swedeland Road
King of Prussia, PA 19406
Entity Type: 03
Legal Representation
Correspondence Address
Ian W. Gillies Knobbe Martens Olson & Bear, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614
United States
Trademark Details
Filing Date
August 30, 2024
Registration Date
May 5, 2026
First Use Anywhere
January 28, 2025
First Use in Commerce
January 28, 2025
Published for Opposition
August 19, 2025
Goods & Services
drug discovery, pharmaceutical drug development, and drug validation services in the field of targeted disease-causing or disease-associated protein degradation; pharmaceutical research and development services, in particular for identifying ubiquitin ligases; providing medical research and scientific information related to ubiquitin ligase identification and targeted disease-causing or disease-associated protein degradation in the fields of pharmaceuticals, biological life sciences, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, and medical research information related to targeted disease-causing or disease-associated protein degradation in the field of pharmaceutical and clinical trials via the internet; consulting services in the fields of pharmaceutical research, biological life sciences, pharmaceutical chemistry, biochemistry, biotechnology, clinical trials, all related to targeted disease-causing or disease-associated protein degradation; research and development of new products in the field of targeted disease-causing or disease-associated protein degradation and the identification of ubiquitin ligases; pharmaceutical, scientific, medical, and clinical research and development services in the field of targeted disease-causing or disease-associated protein degradation; providing information about scientific, pharmaceutical, clinical, and medical research, namely, drug discovery, development and validation information related to a method of ligase selection to discover molecules and drugs that cause targeted disease-causing or disease-associated protein degradation; Scientific and technological services, namely, technical biology consulting services, in particular for identifying ubiquitin ligases